Chemical Component Summary

NameDOXORUBICIN
SynonymsADRIAMYCIN
Identifiers(7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyethanoyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
FormulaC27 H29 N O11
Molecular Weight543.52
TypeNON-POLYMER
Isomeric SMILESC[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](Cc3c2c(c4c(c3O)C(=O)c5cccc(c5C4=O)OC)O)(C(=O)CO)O)N)O
InChIInChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22+,27-/m0/s1
InChIKeyAOJJSUZBOXZQNB-TZSSRYMLSA-N

Chemical Details

Formal Charge0
Atom Count68
Chiral Atom Count6
Bond Count72
Aromatic Bond Count12

Drug Info: DrugBank

DrugBank IDDB00997 
NameDoxorubicin
Groups
  • approved
  • investigational
DescriptionDoxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.
Synonyms
  • Doxorubicin citrate
  • Hydroxydaunorubicin
  • Doxorubicinum
  • 14-hydroxydaunomycin
  • (1S,3S)-3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
Brand Names
  • Doxorubicin Hydrochloride Liposome
  • Adriamycin Rdf Inj 150mg/vial
  • Doxorubicin Hydrochloride
  • Caelyx
  • Lipodox 50
IndicationDoxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.
Categories
  • Anthracycline Topoisomerase Inhibitor
  • Anthracyclines
  • Anthracyclines and Related Substances
  • Antibiotics, Antineoplastic
  • Antineoplastic Agents
ATC-CodeL01DB01
CAS number23214-92-8

Drug Targets

NameTarget SequencePharmacological ActionActions
DNA-unknownintercalation
DNA topoisomerase 2-alphaMEVSPLQPVNENMQVNKIKKNEDAKKRLSVERIYQKKTQLEHILLRPDTY...unknowninhibitor
Nucleolar and coiled-body phosphoprotein 1MADAGIRRVVPSDLYPLVLGFLRDNQLSEVANKFAKATGATQQDANASSL...unknown
Cytochrome P450 3A4MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...unknownsubstrate,inhibitor
Cytochrome P450 2D6MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVD...unknowninhibitor
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
CCDC/CSDBEXTAC
PubChem31703
ChEBICHEBI:28748
ChEMBLCHEMBL53463
PharosCHEMBL53463